Search Medical Condition
Please enter condition
Please choose location from dropdown

Tlalpan, Mexico Clinical Trials

A listing of Tlalpan, Mexico clinical trials actively recruiting patients volunteers.

RESULTS

Found (231) clinical trials

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects 1 Month to <4 Years With Partial-onset Seizures

The trial consists of a 7-day Baseline Period, a 20-day Titration Period, a 7-day Maintenance Period, and a 12-day Transition Period for subjects who complete the study and choose to enter the extension study. Subjects who will not enter the extension study will continue after the Maintenance Period with a ...

Phase

0.0 miles

Learn More »

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to collect additional safety data until apalutamide is commercially available for participants with non-metastatic castrate-resistant prostate cancer (NM-CRPC).

Phase

1.55 miles

Learn More »

Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity

STUDY PROGRAM The study will consist of a previous examination and 4 visits during the follow-up period. Previous visit: pre-admission (Duration approximately 40 minutes) Participants who meet the inclusion criteria will be selected. These will be captured through advertising. Participants will be informed of the characteristics of the study, the ...

Phase N/A

2.34 miles

Learn More »

Treatment Resistant Depression in America Latina

The purpose of this study is to estimate the prevalence of Treatment Resistant Depression (TRD) among Major Depressive Disorder (MDD) participants being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries: Argentina, Brazil, Colombia and Mexico; and to evaluate all and depression-related healthcare ...

Phase N/A

2.4 miles

Learn More »

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.

This is a multi-center, open label, phase IV study to provide continued supply of pasireotide to patients being treated in a current Novartis-sponsored, Oncology CD&MA study and who are benefiting from treatment with pasireotide. Eligible patients are to be consented and can then continue treatment with pasireotide in this protocol. ...

Phase

2.4 miles

Learn More »

Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine (0.5 mg/kg) in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission measured by Magnetic Resonance Imaging Spectroscopy and inflammatory serum markers (IL-6, TNF-alpha).

Phase

2.4 miles

Learn More »

Dapsone for Acute Ischemia Stroke Study

Cerebrovascular diseases are the third cause of mortality around the world. Seventy-five percent of the cases correspond to ischemic stroke, and the remaining 25 % to hemorrhagic infarct. The social impact of Stroke is high as it is the first cause for disabilities. After Stroke, several mechanisms of secondary damage ...

Phase

2.4 miles

Learn More »

Motor Interference Therapy For Traumatic Memories

The investigators treated 10 patients with autobiographical traumatic memories using finger tapping tasks, (Motor Interference Therapy <TIM>)in a pilot study with amazing results and a solid size effect. The investigators decided to challenge the intervention using a control task (Jacobsons progressive relaxation exercises) The hypothesis consists in achieving a 30% ...

Phase N/A

2.4 miles

Learn More »

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine ...

Phase N/A

2.52 miles

Learn More »

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

This study consists of 3 phases: Screening Phase (up to 35 days), an Active Monitoring Phase or a Treatment Phase of 39 cycles or 36 months (whichever occurs first), and a Follow-up Phase which will continue until death, lost to follow-up, consent withdrawal, or study end (approximately 8 years after ...

Phase

2.52 miles

Learn More »